тел. +38 (044) 483-12-82

№3(7) 2024

Укр

DOI 10.37219/2528-8253-2024-3-45

Popovych VI, Koshel IV
A PRAGMATIC, INDIVIDUALLY RANDOMISED, OPEN-LABEL, RETROSPECTIVE STUDY OF THE EFFICACY
OF TOPICAL THERAPY WITH FRAMYCETIN IN THE TREATMENT
OF EXACERBATION OF CHRONIC NASOPHARYNGITIS
Popovych Vasyl I
Lviv Medical University
Head of the Department of Surgery №1
Doctor of Medical Sciences, Professor
E-mail: popovychvasyl@gmail.com
ORCID ID:  https://orcid.org/0000-0002-2898-8474
Koshel Ivanna V
Ivano-Frankivsk National Medical University
Head of the Department of Otolaryngology with a course in head and neck surgery
Doctor of Medical Sciences, Professor
Email: ivannakoshel@gmail.com
ORCID ID:  https://orcid.org/0000-0002-5466-4537
Scopus Author ID: 57218684995

Abstract

The treatment efficacy of chronic nasopharyngitis with systemicantibacterial agents is low. The ineffectiveness of antibiotic therapy is thought to be related to nasopharyngeal bacterial biofilms. The prospect is to influence the bacteria stored in the biofilm, particularly using topical antibacterial agents.

Study purpose: to determine the effect of topical antibacterial therapy with framycetin and add-on treatment on the progression of clinical symptoms in patients with exacerbation of CNP.

Methods: In a pragmatic, individually randomised, open-label, retrospective study, 143 patients receiving endonasal therapy with framycetin solution supplementary to conventional therapy with isotonic seawater solution or additional administration of antihistamines and antiviral agents were randomised. Assessment criteria: reduction in symptom severity: nasal discharge, postnasal drip, hyperaemia, mucosal oedema, assessed using 5-point MSS scale at each visit compared to visit 1, and the course of hyperthermia.

Results: Endonasal therapy with framycetin solution in exacerbation of CNP contributes to the reduction in the severity of the main clinical symptoms in patients of the treatment and control groups. Reduction in the severity of clinical symptoms correlates with a significant decrease in hyperthermia in patients of both groups. Additional administration of antiviral and antihistamine agents does not affect the course of clinical symptoms due to exacerbation of chronic nasopharyngitis.

Conclusion: Framycetin solution for endonasal therapy is a safe and effective agent for etiotropic treatment of exacerbation of chronic nasopharyngitis, and provides a significant therapeutic effect.

Keywords: nasopharyngitis, pharynx, respiratory infections, biofilms, treatment.

Download .PDF

References

  1. Wang H. Chronic adenoiditis. J Int Med Res. 2020 Nov;48(11):300060520971458. doi: 10.1177/ 0300060520971458.
  2. Purnell PR, Ramadan JH, Ramadan HH. Can Symptoms Differentiate Between Chronic Adenoiditis and Chronic Rhinosinusitis in Pediatric Patients. Ear Nose Throat J. 2019 Jun;98(5):279­282. doi: 10.1177/0145561319840133.
  3. Smiianov YV, Smiianov VA, Sniehirova IA, Smiianova OI. Algorithm of adenoiditis treatment in adults, depending on the pharyngeal tonsil hypertrophy stage. Wiad Lek. 2018;71(3 pt 1):564­568.
  4. https://icd.who.int/browse10/2019/en#/J30­J39
  5. https://icd.who.int/browse11/l­m/en
  6. Rajeshwary A, Rai S, Somayaji G, Pai V. Bacteriology of symptomatic adenoids in children. N Am J Med Sci. 2013 Feb;5(2):113­8. doi: 10.4103/1947­2714.107529.
  7. Badran H, Salah M, Fawzy M, Sayed A, Ghaith D. Detection of Bacterial Biofilms in Chronic Pharyngitis Resistant to Medical Treatment. Ann Otol Rhinol Laryngol. 2015 Jul;124(7):567­71. doi: 10.1177/0003489415570934.
  8. Ren T, Glatt DU, Nguyen TN, Allen EK, Early SV, Sale M, Winther B, Wu M. 16S rRNA survey revealed complex bacterial communities and evidence of bacterial interference on human adenoids. Environ Microbiol. 2013 Feb;15(2):535­47. doi: 10.1111/1462­2920.12000.
  9. Van Hoecke H, De Paepe AS, Lambert E, Van Belleghem JD, Cools P, Van Simaey L, Deschaght P, Vaneechoutte M, Dhooge I. Haemophilus influenzae biofilm formation in chronic otitis media with effusion. Eur Arch Otorhinolaryngol. 2016 Nov;273(11):3553­3560. doi: 10.1007/s00405­016­3958­9.
  10. Kania R, Vironneau P, Dang H, Bercot B, Cambau E, Verillaud B, Camous D, Lamers G, Herman P, Vicaut E, Tessier N, Van Den Abbeele T. Bacterial biofilm in adenoids of children with chronic otitis media. Part I: a case control study of prevalence of biofilms in adenoids, risk factors and middle ear biofilms. Acta Otolaryngol. 2019 Apr;139(4):345­350. doi: 10.1080/00016489.2019.1571282.
  11. Dubourg G, Edouard S, Raoult D. Relationship between nasopharyngeal microbiota and patient’s susceptibility to viral infection. Expert Rev Anti Infect Ther. 2019 Jun;17(6):437­447. doi: 10.1080/ 14787210.2019.1621168.
  12. Tozzi AE, Del Chierico F, Pandolfi E, Reddel S, Gesualdo F, Gardini S, et al. Nasopharyngeal microbiota in hospitalized children with Bordetella pertussis and Rhinovirus infection. Sci Rep. 2021 Nov 24;11(1):22858. doi: 10.1038/s41598­021­02322­y.
  13. Edouard S, Million M, Bachar D, Dubourg G, Michelle C, Ninove L, Charrel R, Raoult D. The nasopharyngeal microbiota in patients with viral respiratory tract infections is enriched in bacterial pathogens. Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1725­1733. doi: 10.1007/s10096­018­3305­8.
  14. Miller BJ, Gupta G. Adenoidectomy. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan.
  15. Byars SG, Steams SC, Boomsma JJ. Association of Long­Term Risk of Respiratory, Allergic, and Infectious Diseases with Removal of Adenoids and Tonsils in Childhood JAMA Otolaryngol Head Neck Surg. 2018 Jul;144(7):594­603. doi: 10.1001/jamaoto.2018.0614.
  16. Chao Y, Bergenfelz C, Håkansson AP. In Vitro and In Vivo Biofilm Formation by Pathogenic Streptococci. Methods Mol Biol. 2017;1535:285­299. doi: 10.1007/978­1­4939­6673­8_19.
  17. Bair KL, Campagnari AA. Moraxella catarrhalis Promotes Stable Polymicrobial Biofilms with the Major Otopathogens. Front Microbiol. 2020 Jan 15;10:3006. doi: 10.3389/fmicb.2019.03006.
  18. Luke NR, Jurcisek JA, Bakaletz LO, Campagnari AA. Contribution of Moraxella catarrhalis type IV pili to ­nasopharyngeal colonization and biofilm formation. Infect Immun. 2007 Dec;75(12):5559­64. doi: 10.1128/IAI.00946­07.
  19. Abebe GM. The Role of Bacterial Biofilm in Antibiotic ­Resistance and Food Contamination. Int J Microbiol. 2020 Aug 25;2020:1705814. doi: 10.1155/2020/1705814.
  20. Fokkens W, Lund V, Hopkins HP, Kern R, Reitsma S, Toppila-Salmi S, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020 Feb 20;58(Suppl S29):1-464. doi: 10.4193/Rhin20.600.
  21. https://compendium.com.ua/dec/267493/
  22. Bowers I, Shermetaro C. Adenoiditis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK536931/
  23. Sakarya EU, Bayar Muluk N, Sakalar EG, Senturk M, Aricigil M, Bafaqeeh SA, Cingi C. Use of intranasal corticosteroids in adenotonsillar hypertrophy. J Laryngol Otol. 2017 May;131(5):384­390. doi: 10.1017/S0022215117000408.
  24. Kar M, Altıntoprak N, Muluk NB, Ulusoy S, Bafaqeeh SA, Cingi C. Antileukotrienes in adenotonsillar hypertrophy: a review of the literature. Eur Arch Otorhinolaryngol. 2016 Dec;273(12): 4111­4117. doi: 10.1007/s00405­016­3983­8.
  25. Lou Z. “Commentary to: ‘Endoscopic and clinical benefits of hyaluronic acid in children with chronic adenoiditis and middle ear disease’”? Eur Arch Otorhinolaryngol. 2018 Mar;275(3):827­828. doi: 10.1007/s00405­017­4568­x.